Lenz Therapeutics, Inc. ( ($LENZ) ) has released its Q2 earnings. Here is a breakdown of the information Lenz Therapeutics, Inc. presented to its ...

Final Takeaway Lenz Therapeutics is progressing towards the anticipated launch of LNZ100 in Q4 2025, supported by robust financial resources and strategic pre-launch activities.

(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Monday said that the Food and Drug Administration (FDA) has accepted the company's new drug application for LNZ100 for the treatment of presbyopia.

LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. have entered into an exclusive licensing and commercialization agreement for LNZ100, an aceclidine-based eye drop intended to treat ...